Cardiac Poc Testing Devices Market Size, Share, Growth, and Industry Analysis, By Type (Glucose testing,Hb1Ac Testing,Coagulation testing,Fertility testing,Cardiac markers,Infectious disaese testing,Primary care systems,Heamatology testing,Decentralized clinical chemistry,Others), By Application (Clinics,Hospitals,Home,Assiated living healthcare facilities,Laboratories,Others), Regional Insights and Forecast to 2035

Cardiac POC Testing Devices Market Overview

The global Cardiac Poc Testing Devices Market size is projected to grow from USD 2564.92 million in 2026 to USD 2795.25 million in 2027, reaching USD 7404.53 million by 2035, expanding at a CAGR of 8.98% during the forecast period.

The global Cardiac POC Testing Devices Market was valued at USD 2,844.72 million in 2024, and it is projected to grow steadily to USD 3,105.02 million in 2025. By 2033, the market is expected to reach USD 6,255.38 million, showing strong demand across hospitals, clinics, laboratories, and home healthcare facilities. Among product categories, cardiac marker tests dominate with around 70% market share, while analyzers account for the remaining 30%. Troponin, BNP, CK-MB, and myoglobin tests are among the most widely used cardiac marker assays. Globally, over 32% of annual deaths are due to cardiovascular diseases, representing more than 17 million fatalities per year, which highlights the importance of faster diagnostics. 

The United States represents the largest individual market within North America, accounting for over 40% of the global Cardiac POC Testing Devices Market. In 2024, the U.S. market generated approximately USD 1,368 million, with strong adoption in hospitals, diagnostic laboratories, and emergency departments. The prevalence of cardiovascular diseases in the U.S. remains one of the highest globally, affecting nearly 30 million adults annually. This creates continuous demand for rapid testing solutions. Hospitals and clinics dominate end-user adoption, with more than 55% of hospitals already integrating POC cardiac marker analyzers into their diagnostic pathways. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 32% of global deaths linked to cardiovascular diseases; over 50% of hospital procurement requests focus on cardiac POC solutions.
• Major Market Restraint: 10× higher device cost compared to central lab testing limits adoption across 45% of lower-income healthcare facilities.
• Emerging Trends: 70% of emergency departments now use rapid-result devices; 52% of new systems feature wireless and digital integration.
• Regional Leadership: North America controls 48% share; Europe 30%; Asia-Pacific 15%; Middle East & Africa 7%.
• Competitive Landscape: Top 5 companies hold more than 50% of global share; 48% of new launches emphasize portability.
• Market Segmentation: Cardiac marker tests dominate at 70%; analyzers cover 30%.
• Recent Development: 55% of emergency cardiovascular procedures incorporate POC solutions; 48% of devices launched feature enhanced mobility.

Cardiac POC Testing Devices Market Trends

The Cardiac POC Testing Devices Market is witnessing rapid transformation, with several notable trends shaping the industry. A major trend is the miniaturization and portability of analyzers. More than 50% of newly launched devices in 2023 and 2024 are designed to be handheld or portable, making them suitable for use in ambulances, rural clinics, and home healthcare. This portability trend is expected to cover over 65% of new devices by 2026, aligning with the global demand for decentralized testing. Another significant trend is the integration of digital connectivity. 

Cardiac POC Testing Devices Market Dynamics

DRIVER

"Rising Prevalence of Cardiovascular Diseases"

Cardiovascular diseases account for 32% of annual deaths worldwide, equal to over 17 million people every year. The global burden of acute myocardial infarction and congestive heart failure is creating demand for rapid diagnostic devices.

RESTRAINT

"High Cost of Advanced POC Systems"

The high price of cardiac POC analyzers is a major restraint, with certain advanced devices costing USD 20,000–30,000, compared with less than USD 3,000 for traditional laboratory systems.

OPPORTUNITY

"Expansion of Home Healthcare and Remote Monitoring"

Home healthcare is expanding rapidly, driven by the rising elderly population and remote patient monitoring demand. In 2024, home use of cardiac POC devices accounted for 10% of the market, equivalent to over USD 280 million in value. 

CHALLENGE

"Variability in Regulatory and Reimbursement Policies"

Regulatory and reimbursement environments vary significantly across regions, posing challenges to market adoption. In Europe, more than 40% of countries lack standardized reimbursement codes for cardiac POC tests, slowing uptake. 

Cardiac POC Testing Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Glucose Testing: devices, while primarily used for diabetes management, hold an indirect role in cardiac diagnostics because diabetes is a high-risk factor for cardiovascular diseases.

Glucose testing accounts for USD 785.32 million in 2025, representing 25.1% share, expected to expand to USD 1,678.20 million by 2034 at 9.02% CAGR.

Top 5 Major Dominant Countries in the Glucose Testing Segment

• United States holds USD 248.52 million in 2025 with 31.6% share, projected to reach USD 529.13 million by 2034 at 8.95% CAGR.
• China stands at USD 121.24 million in 2025 with 15.4% share, expanding to USD 260.75 million by 2034 at 9.18% CAGR.
• Germany records USD 84.91 million in 2025 with 10.8% share, forecasted to rise to USD 182.62 million by 2034 at 8.97% CAGR.
• India contributes USD 65.49 million in 2025 with 8.3% share, estimated to reach USD 143.91 million by 2034 at 9.35% CAGR.
• Japan registers USD 59.87 million in 2025 with 7.6% share, expected to achieve USD 129.01 million by 2034 at 9.02% CAGR.

Hb1Ac Testing: devices are used to monitor long-term glucose control. Poor glycemic control increases cardiac risks, and in 2024, Hb1Ac testing devices represented 8% of the POC market share.

Hb1Ac testing represents USD 532.25 million in 2025 with 17.0% share, forecasted to reach USD 1,151.37 million by 2034 at 8.94% CAGR.

Top 5 Major Dominant Countries in the Hb1Ac Testing Segment

• United States achieves USD 165.49 million in 2025, capturing 31.1% share, expanding to USD 356.37 million by 2034 at 8.88% CAGR.
• China posts USD 92.50 million in 2025 with 17.3% share, projected to hit USD 200.31 million by 2034 at 8.97% CAGR.
• United Kingdom stands at USD 55.40 million in 2025 with 10.4% share, expected to increase to USD 120.03 million by 2034 at 8.91% CAGR.
• Japan records USD 48.29 million in 2025 with 9.1% share, rising to USD 104.77 million by 2034 at 8.94% CAGR.
• India contributes USD 43.13 million in 2025 with 8.1% share, projected at USD 93.18 million by 2034 at 9.01% CAGR.

Coagulation Testing: is essential in patients on anticoagulant therapy or presenting with thrombotic events. In 2024, coagulation POC devices captured 9% of market demand, with more than 15 million patients monitored annually using POC INR tests.

The coagulation testing segment is valued at USD 281.37 million in 2025, representing 9% of the global Cardiac POC Testing Devices Market, and is projected to reach USD 611.37 million by 2034 at a CAGR of 8.85%.

Top 5 Major Dominant Countries in the Coagulation Testing Segment

• United States: The U.S. coagulation testing market is valued at USD 94.12 million in 2025, holding 33.5% share, expected to reach USD 204.78 million by 2034 at 8.80% CAGR.
• Germany: Germany is estimated at USD 42.20 million in 2025, representing 15.0% share, and projected to reach USD 91.81 million by 2034 at 8.88% CAGR.
• China: China accounts for USD 39.76 million in 2025, or 14.1% share, anticipated to grow to USD 87.15 million by 2034 at 8.90% CAGR.
• United Kingdom: The UK market is USD 28.11 million in 2025, holding 10% share, expected to expand to USD 61.55 million by 2034 at 8.85% CAGR.
• Japan: Japan represents USD 25.32 million in 2025, with 9% share, and projected to reach USD 55.38 million by 2034 at 8.87% CAGR.

Fertility Testing: though a smaller category, represented about 5% share in 2024. Cardiac links with fertility treatments, especially hormonal imbalances, are being studied.

Fertility testing devices hold a market size of USD 156.62 million in 2025, capturing 5% of the total Cardiac POC Testing Devices Market, projected to reach USD 341.62 million by 2034 at 8.92% CAGR.

Top 5 Major Dominant Countries in the Fertility Testing Segment

• United States: Fertility testing in the U.S. is USD 49.98 million in 2025, capturing 31.9% share, forecast to reach USD 108.89 million by 2034 at 8.88% CAGR.
• China: China’s market is USD 24.37 million in 2025, with 15.6% share, expected to reach USD 53.27 million by 2034 at 8.94% CAGR.
• India: India contributes USD 18.79 million in 2025, representing 12% share, projected to reach USD 41.12 million by 2034 at 9.05% CAGR.
• United Kingdom: The UK market holds USD 16.47 million in 2025, 10.5% share, anticipated to expand to USD 35.92 million by 2034 at 8.90% CAGR.
• Japan: Japan is valued at USD 14.50 million in 2025, capturing 9.3% share, projected to reach USD 31.64 million by 2034 at 8.92% CAGR.

Cardiac Markers: dominate with 70% share in 2024. Troponin tests alone accounted for 45% of total cardiac marker demand, followed by BNP at 15%, CK-MB at 6%, and myoglobin at 4%.

The cardiac markers segment dominates the market with USD 2,192.70 million in 2025, representing 70% of the global market, and projected to reach USD 4,755.12 million by 2034 at 8.96% CAGR.

Top 5 Major Dominant Countries in the Cardiac Markers Segment

• United States: Market size USD 820.20 million in 2025, 37.4% share, expected to reach USD 1,789.56 million by 2034 at 8.92% CAGR.
• Germany: USD 298.03 million in 2025, 13.6% share, projected at USD 646.91 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 184.64 million, 8.4% share, expected to reach USD 400.12 million by 2034 at 8.85% CAGR.
• Japan: USD 155.04 million, 7.1% share, projected to USD 335.98 million by 2034 at 8.88% CAGR.
• China: USD 133.92 million, 6.1% share, expected to reach USD 290.44 million by 2034 at 9.00% CAGR

Infectious Disease Testing: represented 7% of demand in 2024. While not cardiac-specific, infections can worsen heart conditions, making this segment relevant.

The infectious disease testing segment is valued at USD 219.29 million in 2025, 7% share, projected to reach USD 478.66 million by 2034 at 8.91% CAGR.

Top 5 Major Dominant Countries in the Infectious Disease Testing Segment

• United States: USD 80.40 million in 2025, 36.6% share, projected USD 175.30 million by 2034 at 8.88% CAGR.
• Germany: USD 35.60 million, 16.2% share, projected USD 77.67 million by 2034 at 8.89% CAGR.
• China: USD 31.60 million, 14.4% share, projected USD 70.44 million by 2034 at 9.05% CAGR.
• United Kingdom: USD 24.12 million, 11% share, projected USD 53.74 million by 2034 at 8.85% CAGR.
• Japan: USD 18.90 million, 8.6% share, projected USD 42.13 million by 2034 at 8.90% CAGR.

Primary Care Systems: accounted for 6% of global share in 2024. These systems integrate multiple assays including glucose, cholesterol, and troponin into compact analyzers.

Primary care systems in the Cardiac POC Testing Devices Market hold USD 125.30 million in 2025, representing 4% share, expected to reach USD 271.12 million by 2034 at 8.90% CAGR.

Top 5 Major Dominant Countries in the Primary Care Systems Segment

• United States: USD 46.34 million in 2025, 37% share, expected to reach USD 101.15 million by 2034 at 8.88% CAGR.
• Germany: USD 20.15 million, 16.1% share, projected at USD 43.97 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 15.04 million, 12% share, expected to grow to USD 32.86 million by 2034 at 8.85% CAGR.
• Japan: USD 13.20 million, 10.5% share, forecasted at USD 28.78 million by 2034 at 8.92% CAGR.
• China: USD 11.41 million, 9.1% share, expected to reach USD 24.87 million by 2034 at 9.00% CAGR.

Hematology Testing: accounted for 6% of demand, with complete blood count POC devices widely used in smaller labs and clinics.

Hematology testing is projected at USD 94.00 million in 2025, with 3% share, reaching USD 203.67 million by 2034 at 8.93% CAGR.

Top 5 Major Dominant Countries in the Hematology Testing Segment

• United States: USD 33.82 million, 36% share, expected to reach USD 73.21 million by 2034 at 8.88% CAGR.
• Germany: USD 14.15 million, 15% share, projected USD 30.60 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 10.10 million, 10.7% share, projected USD 21.85 million by 2034 at 8.85% CAGR.
• Japan: USD 9.50 million, 10% share, projected USD 20.59 million by 2034 at 8.92% CAGR.
• China: USD 8.40 million, 8.9% share, projected USD 18.21 million by 2034 at 9.00% CAGR.

Decentralized Clinical Chemistry: This segment represented about 4% of usage in 2024. Portable chemistry analyzers are used in mobile clinics and critical care.

Decentralized clinical chemistry devices are valued at USD 62.64 million in 2025, representing 2% of the market, expected to reach USD 135.52 million by 2034 at 8.91% CAGR.

Top 5 Major Dominant Countries in the Decentralized Clinical Chemistry Segment

• United States: USD 23.35 million, 37.3% share, projected USD 50.55 million by 2034 at 8.88% CAGR.
• Germany: USD 11.03 million, 17.6% share, projected USD 23.88 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 7.52 million, 12% share, projected USD 16.35 million by 2034 at 8.85% CAGR.
• Japan: USD 6.82 million, 10.9% share, projected USD 14.83 million by 2034 at 8.92% CAGR.
• China: USD 5.91 million, 9.4% share, projected USD 12.91 million by 2034 at 9.00% CAGR.

Others: testing types, including lipid profiling and metabolic screening, accounted for 3% share in 2024. These are increasingly important as more than 39% of adults worldwide are overweight, raising cardiac risk factors.

The “Others” segment, including emerging cardiac POC devices and integrated systems, is valued at USD 62.64 million in 2025, holding 2% share, projected to reach USD 135.52 million by 2034 at 8.91% CAGR.

Top 5 Major Dominant Countries in the Others Segment

• United States: USD 23.35 million in 2025, 37.3% share, expected to reach USD 50.55 million by 2034 at 8.88% CAGR.
• Germany: USD 11.03 million, 17.6% share, projected USD 23.88 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 7.52 million, 12% share, projected USD 16.35 million by 2034 at 8.85% CAGR.
• Japan: USD 6.82 million, 10.9% share, projected USD 14.83 million by 2034 at 8.92% CAGR.
• China: USD 5.91 million, 9.4% share, projected USD 12.91 million by 2034 at 9.00% CAGR.

BY APPLICATION

Clinics: accounted for 25% of demand in 2024. More than 50,000 clinics worldwide use POC cardiac devices, especially troponin and glucose analyzers.

The clinics segment holds USD 783.10 million in 2025, representing 25% of the global Cardiac POC Testing Devices Market, projected to reach USD 1,698.32 million by 2034 at 8.95% CAGR.

Top 5 Major Dominant Countries in the Clinics Segment

• United States: USD 246.93 million in 2025, 31.5% share, expected to reach USD 534.12 million by 2034 at 8.88% CAGR.
• Germany: USD 123.30 million, 15.8% share, projected to reach USD 266.91 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 94.00 million, 12% share, projected to reach USD 202.34 million by 2034 at 8.85% CAGR.
• Japan: USD 78.31 million, 10% share, projected to reach USD 168.62 million by 2034 at 8.92% CAGR.
• China: USD 61.56 million, 7.9% share, expected to reach USD 133.74 million by 2034 at 9.00% CAGR

Hospitals: dominate the market with 45% share. In 2024, more than 100,000 hospitals worldwide used cardiac POC devices.

Hospitals dominate the market with USD 1,412.72 million in 2025, representing 45% share, projected to reach USD 3,062.44 million by 2034 at 8.98% CAGR.

Top 5 Major Dominant Countries in the Hospitals Segment

• United States: USD 678.96 million, 48% share, expected to reach USD 1,475.12 million by 2034 at 8.92% CAGR.
• Germany: USD 212.00 million, 15% share, projected to reach USD 456.12 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 127.14 million, 9% share, projected to reach USD 273.48 million by 2034 at 8.85% CAGR.
• Japan: USD 104.94 million, 7.4% share, projected to reach USD 228.92 million by 2034 at 8.92% CAGR.
• China: USD 89.56 million, 6.3% share, projected to reach USD 198.01 million by 2034 at 9.00% CAGR

Home: use accounted for 10% share in 2024. Approximately 25 million units of home-use cardiac and glucose monitoring kits were sold. This segment is growing with chronic disease management and aging populations.

The home healthcare segment is valued at USD 313.24 million in 2025, representing 10% share, projected to reach USD 680.25 million by 2034 at 8.95% CAGR.

Top 5 Major Dominant Countries in the Home Healthcare Segment

• United States: USD 124.96 million in 2025, 39.9% share, projected to reach USD 271.25 million by 2034 at 8.88% CAGR.
• Germany: USD 45.89 million, 14.6% share, projected to reach USD 99.21 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 34.12 million, 10.9% share, projected to reach USD 73.78 million by 2034 at 8.85% CAGR.
• Japan: USD 27.81 million, 8.9% share, projected to reach USD 60.18 million by 2034 at 8.92% CAGR.
• China: USD 21.46 million, 6.8% share, projected to reach USD 46.54 million by 2034 at 9.00% CAGR.

Assisted Living Healthcare Facilities: This segment contributed 7% share in 2024. Assisted living centers, especially in North America and Europe, deploy portable analyzers. More than 10,000 facilities reported regular use of cardiac POC kits.

Assisted living facilities account for USD 125.30 million in 2025, representing 4% share, projected to reach USD 271.12 million by 2034 at 8.90% CAGR.

Top 5 Major Dominant Countries in the Assisted Living Segment

• United States: USD 46.34 million, 37% share, projected to reach USD 101.15 million by 2034 at 8.88% CAGR.
• Germany: USD 20.15 million, 16.1% share, projected to reach USD 43.97 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 15.04 million, 12% share, projected to reach USD 32.86 million by 2034 at 8.85% CAGR.
• Japan: USD 13.20 million, 10.5% share, projected to reach USD 28.78 million by 2034 at 8.92% CAGR.
• China: USD 11.41 million, 9.1% share, projected to reach USD 24.87 million by 2034 at 9.00% CAGR.

Laboratories: represented 18% of demand. Although centralized labs dominate in test volume, over 20 million POC cardiac marker kits were processed in labs globally in 2024. Diagnostic accuracy and workflow integration drive this segment.

Laboratories contribute USD 502.05 million in 2025, capturing 18% share, projected to reach USD 1,088.33 million by 2034 at 8.95% CAGR.

Top 5 Major Dominant Countries in the Laboratories Segment

• United States: USD 190.74 million, 38% share, projected to reach USD 414.20 million by 2034 at 8.88% CAGR.
• Germany: USD 85.36 million, 17% share, projected to reach USD 185.28 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 53.23 million, 10.6% share, projected to reach USD 115.52 million by 2034 at 8.85% CAGR.
• Japan: USD 43.18 million, 8.6% share, projected to reach USD 93.65 million by 2034 at 8.92% CAGR.
• China: USD 39.54 million, 7.9% share, projected to reach USD 85.75 million by 2034 at 9.00% CAGR.

Others: settings, including military bases, ambulances, and remote clinics, contributed 5% share in 2024. In total, more than 8,000 mobile healthcare units use POC analyzers worldwide.

Other applications, including research centers and specialized cardiac clinics, hold USD 62.64 million in 2025, representing 2% share, projected to reach USD 135.52 million by 2034 at 8.91% CAGR.

Top 5 Major Dominant Countries in the Others Segment

• United States: USD 23.35 million, 37.3% share, projected to reach USD 50.55 million by 2034 at 8.88% CAGR.
• Germany: USD 11.03 million, 17.6% share, projected to reach USD 23.88 million by 2034 at 8.90% CAGR.
• United Kingdom: USD 7.52 million, 12% share, projected to reach USD 16.35 million by 2034 at 8.85% CAGR.
• Japan: USD 6.82 million, 10.9% share, projected to reach USD 14.83 million by 2034 at 8.92% CAGR.
• China: USD 5.91 million, 9.4% share, projected to reach USD 12.91 million by 2034 at 9.00% CAGR.

Cardiac POC Testing Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

dominates with a 48% share of the global market in 2024, equivalent to approximately USD 1,365 million. The U.S. is the largest contributor, while Canada and Mexico together account for nearly 10% of regional demand.

The North America Cardiac POC Testing Devices Market is valued at USD 1,245.20 million in 2025, representing 39.7% of the global market, and projected to reach USD 2,691.33 million by 2034 at 8.92% CAGR.

North America – Major Dominant Countries in the Market

• United States: Market size is USD 1,050.45 million in 2025, holding 84.4% share of North America, projected to reach USD 2,271.22 million by 2034 at 8.88% CAGR. Rapid adoption of troponin and BNP POC testing devices supports over 35 million tests annually.
• Canada: USD 124.20 million, 10% share, projected to reach USD 268.50 million by 2034 at 8.85% CAGR. Hospitals and clinics perform over 4 million POC tests annually.
• Mexico: USD 45.10 million, 3.6% share, projected to reach USD 97.22 million by 2034 at 9.00% CAGR. Rising cardiovascular disease awareness drives testing adoption.
• Puerto Rico: USD 15.32 million, 1.2% share, projected to reach USD 33.05 million by 2034 at 8.90% CAGR. Small clinics are adopting portable POC analyzers.
• Costa Rica: USD 10.13 million, 0.8% share, projected to reach USD 21.34 million by 2034 at 8.95% CAGR. Government initiatives support deployment in rural healthcare centers.

EUROPE

held a 30% share in 2024, equal to nearly USD 850 million. Germany, France, and the UK lead the regional market, contributing more than 65% of demand. Germany alone accounts for 22% of Europe’s share, with over 1,500 hospitals adopting rapid troponin testing.

The European market is valued at USD 892.56 million in 2025, representing 28.5% of the global Cardiac POC Testing Devices Market, expected to reach USD 1,932.24 million by 2034 at 8.90% CAGR.

Europe – Major Dominant Countries in the Market

• Germany: USD 298.03 million in 2025, 33.4% share, projected to reach USD 646.91 million by 2034 at 8.90% CAGR. Hospitals perform over 12 million POC tests annually.
• United Kingdom: USD 184.64 million, 20.7% share, projected to reach USD 400.12 million by 2034 at 8.85% CAGR. Adoption of emergency cardiac POC testing is widespread.
• France: USD 92.56 million, 10.4% share, projected to reach USD 200.74 million by 2034 at 8.88% CAGR. Laboratories conduct over 5 million tests annually.
• Italy: USD 73.20 million, 8.2% share, projected to reach USD 158.97 million by 2034 at 8.90% CAGR. Home-based POC devices are increasingly utilized.
• Spain: USD 44.13 million, 4.9% share, projected to reach USD 96.13 million by 2034 at 8.92% CAGR. Assisted living facilities and clinics contribute to rising demand.

ASIA-PACIFIC

accounted for 15% share in 2024, valued at nearly USD 425 million. China represents 40% of regional demand, followed by India at 25% and Japan at 20%. China reported over 1 million troponin tests using POC devices in 2024.

The Asia-Pacific market is valued at USD 651.50 million in 2025, representing 20.7% share, projected to reach USD 1,404.85 million by 2034 at 9.00% CAGR.

Asia – Major Dominant Countries in the Market

• China: USD 219.76 million, 33.7% share, projected to reach USD 474.55 million by 2034 at 9.05% CAGR. Hospitals conduct over 20 million tests annually.
• Japan: USD 155.04 million, 23.8% share, projected to reach USD 335.98 million by 2034 at 8.92% CAGR. Emergency departments and laboratories are primary adopters.
• India: USD 94.50 million, 14.5% share, projected to reach USD 203.41 million by 2034 at 9.10% CAGR. Clinics and home healthcare centers are expanding POC test adoption.
• South Korea: USD 62.64 million, 9.6% share, projected to reach USD 135.52 million by 2034 at 8.95% CAGR. Increasing elderly population drives demand.
• Australia: USD 41.56 million, 6.4% share, projected to reach USD 90.01 million by 2034 at 8.90% CAGR. Assisted living facilities contribute significantly to testing volume.

MIDDLE EAST & AFRICA

region contributed 7% share in 2024, equal to about USD 200 million. South Africa leads adoption in Africa, with 35% share of regional demand. In the Middle East, Saudi Arabia and the UAE together represent 40% of market usage.

The Middle East & Africa market is valued at USD 345.16 million in 2025, representing 11% of the global market, expected to reach USD 754.12 million by 2034 at 8.95% CAGR.

Middle East & Africa – Major Dominant Countries in the Market

• Saudi Arabia: USD 123.05 million, 35.6% share, projected to reach USD 268.74 million by 2034 at 8.90% CAGR. Hospitals conduct over 5 million POC cardiac tests annually.
• United Arab Emirates: USD 76.14 million, 22% share, projected to reach USD 166.25 million by 2034 at 8.88% CAGR. Private hospitals are major adopters.
• South Africa: USD 41.34 million, 12% share, projected to reach USD 90.31 million by 2034 at 8.92% CAGR. Assisted living and clinics are expanding POC adoption.
• Egypt: USD 38.56 million, 11.2% share, projected to reach USD 84.12 million by 2034 at 8.95% CAGR. Government initiatives support rural healthcare deployment.
• Nigeria: USD 29.07 million, 8.4% share, projected to reach USD 63.41 million by 2034 at 9.00% CAGR. Growing private healthcare sector drives adoption.

List of Top Cardiac POC Testing Devices Companies

• Abbott Laboratories
• Alere Inc.
• Roche Diagnostics
• Boston Scientific Corp
• Beckman Coulter Inc.
• Medtronic Inc.
• BG Medicine Inc.
• Randox Laboratories Ltd.

Abbott Laboratories: holds nearly 20% of global share, with over 100,000 analyzers installed worldwide.

Roche Diagnostics: controls around 18% share, with more than 80,000 units deployed in hospitals and labs globally.

Investment Analysis and Opportunities

Investments in the Cardiac POC Testing Devices Market are intensifying as healthcare systems prioritize faster diagnostic capabilities. In 2024, over USD 500 million was invested globally into new product development, clinical validation, and manufacturing expansion for POC cardiac devices. Venture capital funding increased by 30% year-on-year, particularly targeting startups developing handheld troponin and BNP analyzers. Hospitals are making significant procurement investments. In North America alone, more than 2,000 hospitals upgraded to new-generation portable analyzers in 2023–2024, representing procurement worth USD 200 million. European healthcare providers spent over USD 150 million during the same period, particularly in Germany, the UK, and France.

New Product Development

Innovation is driving the Cardiac POC Testing Devices Market, with manufacturers focusing on speed, accuracy, and integration. In 2024, more than 45% of new launches were handheld devices designed for rapid deployment. Several companies introduced all-in-one platforms capable o running multiple cardiac assays in under 10 minutes. Digital integration is a key innovation. Over 50% of new devices now feature wireless connectivity and electronic medical record integration. Some systems allow real-time result sharing with cardiologists, improving collaboration across healthcare networks. Manufacturers are also focusing on multiplex testing. In 2024, about 28% of new POC devices could test for more than one marker simultaneously, reducing consumable costs by nearly 30% for hospitals. Portable cartridges now combine troponin and BNP tests, streamlining acute care workflows.

Five Recent Developments

• Abbott launched a new portable troponin analyzer in 2023, capable of delivering results in under 7 minutes.
• Roche introduced a wireless-enabled POC BNP device in 2024, now used in over 5,000 hospitals globally.
• Beckman Coulter unveiled a multipanel analyzer in 2024, supporting five simultaneous cardiac assays.
• Medtronic partnered with hospitals in 2024 to deploy over 10,000 handheld devices across North America.
• Randox Laboratories launched an eco-friendly cartridge line in 2025, reducing test-related waste by 25%.

Report Coverage of Cardiac POC Testing Devices Market

The Cardiac POC Testing Devices Market Report provides comprehensive insights into the global industry. The report covers market size, share, segmentation, and regional performance from 2024 through 2033. The study examines both product and application segments, with a focus on cardiac markers, which hold a 70% share of the market. It further explores applications across hospitals, clinics, laboratories, home use, and assisted living facilities. Regional analysis highlights North America’s dominance with a 48% share, Europe’s strong contribution of 30%, and Asia-Pacific’s rapid growth trajectory. Middle East & Africa and Latin America are also detailed, showing emerging demand. T

Key drivers, restraints, opportunities, and challenges are analyzed with facts and figures, including the impact of rising cardiovascular disease prevalence, device affordability, and regulatory barriers. The report also details investment trends, with over USD 500 million in new funding recorded globally in 2024. In addition, the report outlines recent innovations such as handheld analyzers, multiplex testing platforms, wireless-enabled devices, and eco-friendly cartridges.

Cardiac Poc Testing Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2564.92 Million in 2026
Market Size Value By	USD 7404.53 Million by 2035
Growth Rate	CAGR of 8.98% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Glucose testing Hb1Ac Testing Coagulation testing Fertility testing Cardiac markers Infectious disaese testing Primary care systems Heamatology testing Decentralized clinical chemistry Others By Application : Clinics Hospitals Home Assiated living healthcare facilities Laboratories Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample